Monographie - Erythromycin lactobionate

viimane versioon :
19/11/2024

Erythromycin lactobionate

keemiline struktuur

Kaubanduslikud nimed erinevates maades

Preparaatide nimed on näitlikud ja abianete sisaldus võib erineda sõltuvalt riigist ja laborist

Abboticin	Norra, Rootsi, Soome, Taani
Eristin	Argentiina
Erithromicina	Tšiili
Erycinum	Saksamaa
Erythrocin	Ameerika ühendriigid, Austraalia, Iirimaa, Kanada, Saksamaa, Saudi Araabia, Suurbritannia, uus-Meremaa
Erythrocin lactobionat ADD Vantage	Austraalia, Austria
Erythrocine	Belgia, Holland, Luksemburg, Prantsusmaa, Tuneesia
Erythromycin	Ameerika ühendriigid, Saksamaa, Suurbritannia, Ungari
Erythromycine	Luksemburg
Erythromycinum	Poola
Pantomicina	Hispaania, Tšiili

Viited : Erythromycin lactobionate

	tüüp	avaldamine
20	ajaleht	Pluta PL, Morgan PK. Stability of erythromycin in intravenous admixtures. Am J Hosp Pharm 1986 ; 43: 2732,2738.
22	ajaleht	Sewell GJ, Palmer AJ. The chemical and physical stability of three intravenous infusions subjected to frozen storage and microwave thawing. Int J Pharm 1991 ; 72: 57-63.
73	ajaleht	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
93	ajaleht	Hutchings SR, Rusho WJ, Tyler LS. Compatibility of cefmetazole sodium with commonly used drugs during Y-site delivery. Am J Health-Syst Pharm 1996 ; 53: 2185-2188.
186	ajaleht	Swart EL, Mooren RAG, Van Loenen AC. Compatibility of midazolam hydrochloride and lorazepam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2020-2022.
198	ajaleht	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
317	ajaleht	Kershaw BP, Monnier HL, Mason JH. Visual compatibility of premixed theophylline or heparin with selected drugs for IV administration. Am J Hosp Pharm 1993 ; 50: 1360-1362.
336	ajaleht	Forman JK, Lachs JR, Souney PF. Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection. Am J Hosp Pharm 1987 ; 44: 1408-1409.
337	ajaleht	Bashaw ED, Amantea MA, Minor JR, Galleli JF. Visual compatibility of zidovudine with other drugs during simulated Y-site administration. Am J Hosp Pharm 1988 ; 45: 2532-2533.
384	ajaleht	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of esmolol hydrochloride and various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 630-632.
385	ajaleht	Benedict MK, Roche VF, Banakar UV, Hilleman DE. Visual compatibility of amiodarone hydrochloride with various antimicrobial agents during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1117-1118.
386	ajaleht	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1357-1358.
397	ajaleht	Fong PA, Ward J. Visual compatibility of intravenous famotidine with selected drugs. Am J Hosp Pharm 1989 ; 46: 125-126.
405	ajaleht	Nieves-Cordero AL, Luciw HM, Souney PF. Compatibility of narcotic analgesic solutions with various antibiotics during simulated Y-site injection. Am J Hosp Pharm 1985 ; 42: 1108-1109.
479	ajaleht	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
491	ajaleht	Turowski RC, Durthaler JM. Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2181-2184.
496	ajaleht	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
573	ajaleht	Dinel BA, Ayotte DL, Behme RJ, Black BL, Whitby JL. Stability of antibiotic admixtures frozen in minibags. Drug Intell Clin Pharm 1977 ; 11: 542-548.
805	ajaleht	Oskroba DM, Leissing NC, Trissel LA. An automated process for determining the physical compatibility of drugs. Hosp Pharm 1997 ; 32: 1013-1020.
939	ajaleht	Gilbar PJ, Groves CF. Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection. Aust J Hosp Pharm 1994 ; 24: 167-170.
999	ajaleht	Watson D. Piggyback compatibility of antibiotics with pediatric parenteral nutrition solution. JPEN 1985 ; 9: 220-224.
1047	ajaleht	Souney PF, Colucci RD, Mariani G, Campbell D. Compatibility of magnesium sulfate solutions with various antibiotics during simulated Y-site injection. Am J Hosp Pharm 1984 ; 41: 323-324.
1057	ajaleht	Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207.
1135	ajaleht	Baltz JK, Kennedy P, Minor JR, Gallelli J. Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1990 ; 47: 2075-2077.
1153	ajaleht	Allwood MC. The influence of buffering on the stability of erythromycin injection in small-volume infusions. Int J Pharm 1992 ; 80: R7-R9.
1154	ajaleht	Allwood MC. The stability of erythromycin injection in small-volume infusions. Int J Pharm 1990 ; 62: R1-R3.
1201	ajaleht	Yuhas EM, Lofton FT, Rosenberg HA, Mayron D, Baldinus JG. Cimetidine hydrochloride compatibility III: Room temperature stability in drug admixtures. Am J Hosp Pharm 1981 ; 38: 1919-1922.
1232	ajaleht	Beatson C, Taylor A. A physical compatibility study of furosemide & flucloxacillin injections. Br J Pharm Pract 1987 ; 9: 223-226, 236.
1315	ajaleht	Halpern NA, Colucci RD, Alicea M, Greenstein R. Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297.
1490	ajaleht	Halpern NA, Colucci RD, Alicea M, Greenstein R. The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254.
1607	ajaleht	Trissel LA, Zhang Y, Xu QA. Incompatibility of erythromycin lactobionate and sulfamethoxazole/trimethoprim with linezolid injection. Hosp Pharm 2000 ; 35: 1192-1196.
1712	ajaleht	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	ajaleht	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	ajaleht	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1759	ajaleht	Servais H, Tulkens PM. Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients. Antimicrob Agents Chemother 2001 ; 45: 2643-2647.
1802	ajaleht	Bell MS, Nolt DH. Visual compatibility of doxapram hydrochloride with drugs commonly administered via a Y-site in the intensive care nursery. Am J Health-Syst Pharm 2003 ; 60: 193-194.
1803	ajaleht	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1925	ajaleht	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1982	ajaleht	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2141	ajaleht	Barinian N, Chanteux H, Viaene E, Servais H, Tulkens PM. Stability and compatibility study of cefepime in comparaison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units. J Antimicrob Chemother 2003 ; 51: 651-658.
2231	ajaleht	de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother 2008 ; 61, 2: 382-388.
3012	ajaleht	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3216	ajaleht	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3385	ajaleht	Raverdi V, Ampe E, Hecq JD, Tulkens PM. Stability and compatibility of vancomycin for administration by continuous infusion. J Antimicrob Chemother 2013 ; 68: 1179-1182.
3408	ajaleht	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3520	Labor	Cidomycin - Summary of product Chracteristics. Sanofi 2011
3540	Labor	Heparin sodium - Summary of Product Characteristics. Wockhardt 2010
3549	Labor	Amikacine B Braun - Résumé des caractéristiques du produit. B Braun 2012
3560	Labor	Linezolid (Zyvox®) - Summary of Product Characteristics Pharmacia 2013
3564	Labor	Rocuronium B Braun - Résumé des caractéristiques du produit. B Braun 2012
3602	Labor	Mesna (Uromitexan®)- Summary of Product Characteristics Baxter SAS 2013
3643	Labor	Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics Sanofi 2015
3674	Labor	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3766	ajaleht	Forrest J.M, Hildgen P. Compatibilité de l’acétylcystéine injectable lors de son administration en Y avec d’autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3767	ajaleht	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3824	ajaleht	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3964	ajaleht	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
4319	ajaleht	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4603	ajaleht	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4742	ajaleht	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.

Mentions Légales